Marpai Inc MRAI

NAS: MRAI | ISIN: US5713541093   17/05/2024
2,100 USD (+3,96%)
(+3,96%)   17/05/2024

9 mei 2024 · Marpai Reports First Quarter 2024 Financial Results · Persbericht

3 mei 2024 · Marpai To Host Webcast On May 10, 2024 To Discuss First Quarter 2024 Financial Results · Persbericht

2 mei 2024 · Marpai Inc. Announces Cost Reduction Program And Property Sublease · Persbericht

24 april 2024 · Marpai Inc. Bolsters Sales Team With Two World-Class Executives · Persbericht

16 april 2024 · Marpai Inc. Announces Sale Of $11.83 Million Convertible Notes · Persbericht

26 maart 2024 · Marpai Reports Fourth Quarter And Full Year 2023 Financial Results · Persbericht

13 maart 2024 · Nasdaq Panel Grants Marpai's Request For Extension To Comply With Continued Listing Requirements · Persbericht

6 maart 2024 · Marpai Announces Preliminary Unaudited Financial Results For Fourth Quarter And Full Year 2023 · Persbericht

5 maart 2024 · MARPAI ANNOUNCES "OFF-CYCLE" NEW CLIENT AGREEMENT · Persbericht

8 februari 2024 · Marpai Announces Key Financial Agreements · Persbericht

12 januari 2024 · Marpai Hires John Powers As President · Persbericht

13 december 2023 · Marpai, Inc. Announces Appointment Of Two New Independent Directors · Persbericht

6 december 2023 · Marpai, Inc. Regains Compliance With Nasdaq Minimum Bid Price Compliance · Persbericht

2 december 2023 · Marpai, Inc. Confirms It Has Filed An Appeal To Nasdaq Delisting Letter · Persbericht

6 november 2023 · Marpai Names Damien Lamendola as Chief Executive Officer to Drive the Next Phase of its Growth · Persbericht

3 augustus 2023 · Marpai, Inc. Reports Second Quarter 2023 Results · Persbericht

27 juli 2023 · Marpai To Host Call On August 3, 2023 To Discuss Second Quarter 2023 Financial Results · Persbericht

18 juli 2023 · Marpai Launches New Health Plan For Small Employers · Persbericht

5 juli 2023 · Marpai Collaborates With Nuvoair To Offer Value-Based Cardiopulmonary Care To Self-Funded Employer Health Plans · Persbericht

29 juni 2023 · Marpai Confirms Revenue Guidance for Q2 2023 of $9.5 Million to $9.8 Million · Persbericht

Mijn selecties